Dr Frédéric Triebel | Chief Scientific Officer and Medical Officer
Prima Biomed, Ltd

Dr Frédéric Triebel, Chief Scientific Officer and Medical Officer, Prima Biomed, Ltd

Frédéric Triebel, MD. Ph.D., is the scientific founder of Immutep S.A. (2001). Before starting Immutep, he was Professor in Immunology at Paris University. While working at Institut Gustave Roussy (IGR), a large cancer centre in Paris, he
discovered the LAG-3 gene in 1990 and continued working on this research program since then, identifying the functions and medical usefulness of this molecule. He headed a research group at IGR while being also involved in the biological
follow-up of cancer patients treated in Phase I/II immunotherapy trials. He was Director of an INSERM Unit from 1991 to 1996.
First trained as a clinical haematologist, Dr. Triebel holds a Ph.D. in immunology (Paris University) and successfully developed several research programs in immunogenetics, leading to 145 publications and 18 patents.
Immutep is now part of Prima Biomed Ltd and Dr. Triebel serves as the CSO/CMO of the company.


Advanced Therapies and Regenerative Medicine Day 2 - Thursday 17th May 2018 @ 09:50

LAG-3: the next immune checkpoint after CTLA-4 and PD-1/PDL-1?

  • LAG-3/ MHC class II interactions and their modulation in both cancer and auto-immune diseases
  • Combination therapy with anti-LAG-3 and anti-PD-1 mAb in oncology: where do we stand?
  • Combination therapy with eftilagimod alpha (LAG-3Ig) and chemotherapy or anti-PD-1 mAb

back to speakers



Erica Baeta
+44 (0)207 092 1152


Jessica Robinson
t/ +44 (0)207 092 1150


Issa Mauthoor
+44 (0)207 092 1257